Nanoreporter PET predicts the efficacy of anti-cancer nanotherapy

Nature Communications

Volumn 7, Issue , 2016, Pages

  Pérez Medina, Carlos ^a,b,c   Abdel Atti, Dalya ^d   Tang, Jun ^d   Zhao, Yiming ^a   Fayad, Zahi A ^a   Lewis, Jason S ^d,e   Mulder, Willem J M ^a,f   Reiner, Thomas ^d,e  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e NEW YORK MEDICAL COLLEGE   (United States)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; NANOPARTICLE; NANOREPORTER ZR 89; PACLITAXEL; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; MACROGOL; ZIRCONIUM;

CANCER; DRUG; NANOPARTICLE; NANOTECHNOLOGY; NUMERICAL MODEL; RODENT; SURVIVAL; TOMOGRAPHY; TUMOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER MODEL; CANCER SURVIVAL; CANCER THERAPY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG MONITORING; DRUG RETENTION; DRUG TUMOR LEVEL; DRUG UPTAKE; FEMALE; MOUSE; NANOPHARMACEUTICS; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVITY; TUMOR GROWTH; TUMOR VOLUME; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; DIAGNOSTIC IMAGING; DRUG ADMINISTRATION; EXPERIMENTAL MAMMARY NEOPLASM; HUMAN; MORTALITY; PATHOLOGY; PROCEDURES; SURVIVAL ANALYSIS; THERANOSTIC NANOMEDICINE; TISSUE DISTRIBUTION; TRANSPORT AT THE CELLULAR LEVEL;

MUS;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BIOLOGICAL TRANSPORT; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NANOPARTICLES; POLYETHYLENE GLYCOLS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SURVIVAL ANALYSIS; THERANOSTIC NANOMEDICINE; TISSUE DISTRIBUTION; ZIRCONIUM;

EID: 84975495648     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms11838     Document Type: Article

References (28)

1. Barenholz, Y. Doxil(R)-the first FDA-approved nano-drug: lessons learned. J. Control Release 160, 117-134 (2012).
2. Torchilin, V. P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4, 145-160 (2005).
3. Chow, E. K., Ho, D. Cancer nanomedicine: from drug delivery to imaging. Sci. Transl. Med. 5, 216rv4 (2013).
4. Prabhakar, U. et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 73, 2412-2417 (2013).
5. Gaitanis, A., Staal, S. Liposomal doxorubicin and nab-paclitaxel: nanoparticle cancer chemotherapy in current clinical use. Methods Mol. Biol. 624, 385-392 (2010).
6. Staropoli, N. et al. Pegylated liposomal doxorubicin in the management of ovarian cancer: a systematic review and metaanalysis of randomized trials. Cancer Biol. Ther. 15, 707-720 (2014).
7. Duggan, S. T., Keating, G. M. Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDSrelated Kaposi's sarcoma. Drugs 71, 2531-2558 (2011).
8. Montana, M. et al. Albumin-bound paclitaxel: the benefit of this new formulation in the treatment of various cancers. J. Chemother. 23, 59-66 (2011).
9. Hirsh, V. nab-paclitaxel for the management of patients with advanced nonsmall-cell lung cancer. Expert Rev. Anticancer Ther. 14, 129-141 (2014).
10. Bertrand, N., Wu, J., Xu, X., Kamaly, N., Farokhzad, O. C. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Deliv. Rev. 66, 2-25 (2014).
11. Dawidczyk, C. M. et al. State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines. J. Control Release 187, 133-144 (2014).
12. Gabizon, A., Shmeeda, H., Grenader, T. Pharmacological basis of pegylated liposomal doxorubicin: impact on cancer therapy. Eur. J. Pharm. Sci. 45, 388-398 (2012).
13. Weissleder, R., Pittet, M. J. Imaging in the era of molecular oncology. Nature 452, 580-589 (2008).
14. Lammers, T., Rizzo, L. Y., Storm, G., Kiessling, F. Personalized nanomedicine. Clin. Cancer Res. 18, 4889-4894 (2012).
15. Sanhai, W. R., Sakamoto, J. H., Canady, R., Ferrari, M. Seven challenges for nanomedicine. Nat. Nanotechnol. 3, 242-244 (2008).
16. Mulder, W. J., Jaffer, F. A., Fayad, Z. A., Nahrendorf, M. Imaging and nanomedicine in inflammatory atherosclerosis. Sci. Transl. Med. 6, 239sr1 (2014).
17. Lluch, A. et al. Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors. Crit. Rev. Oncol. Hematol. 89, 62-72 (2014).
18. Chen, F., Ehlerding, E. B., Cai, W. Theranostic nanoparticles. J. Nucl. Med. 55, 1919-1922 (2014).
19. Bulte, J. W. Hot spot MRI emerges from the background. Nat. Biotechnol. 23, 945-946 (2005).
20. Zheng, J., Jaffray, D., Allen, C. Quantitative CT imaging of the spatial and temporal distribution of liposomes in a rabbit tumor model. Mol. Pharm. 6, 571-580 (2009).
21. Bashir, M. R., Bhatti, L., Marin, D., Nelson, R. C. Emerging applications for ferumoxytol as a contrast agent in MRI. J. Magn. Reson. Imaging 41, 884-898 (2015).
22. Hrkach, J. et al. Preclinical development and clinical translation of a PSMAtargeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl. Med. 4, 128ra39 (2012).
23. Gabizon, A. et al. Cancer nanomedicines: closing the translational gap. Lancet 384, 2175-2176 (2014).
24. Perez-Medina, C. et al. A modular labeling strategy for in vivo PET and nearinfrared fluorescence imaging of nanoparticle tumor targeting. J. Nucl. Med. 55, 1706-1711 (2014).
25. Holland, J. P., Sheh, Y., Lewis, J. S. Standardized methods for the production of high specific-activity zirconium-89. Nucl. Med. Biol. 36, 729-739 (2009).
26. Laginha, K. M., Verwoert, S., Charrois, G. J., Allen, T. M. Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin. Cancer Res. 11, 6944-6949 (2005).
27. Smith-Jones, P. M., Solit, D. B. Generation of DOTA-conjugated antibody fragments for radioimmunoimaging. Methods Enzymol. 386, 262-275 (2004).
28. Liu, C. M. et al. Comparison of the therapeutic efficacy of 188Rheniumliposomes and liposomal doxorubicin in a 4T1 murine orthotopic breast cancer model. Oncol. Rep. 27, 678-684 (2012).